Yahoo Search Búsqueda en la Web

Resultado de búsqueda

1. www.ser.es › la-radiacion-solar-puede-ser-una-causa-desencadenante-del-lupusLa radiación solar puede ser una causa desencadenante del lupus

   www.ser.es › la-radiacion-solar-puede-ser-una-causa-desencadenante-del-lupus

   • En caché

   Hace 10 horas · Con motivo del Día Mundial del Lupus, 10 de mayo, la Sociedad Española de Reumatología, junto con FELUPUS y GSK, se unen para aumentar la visibilidad de esta enfermedad. En España se estima que el Lupus Eritematoso Sistémico (LES) tiene una prevalencia del 0,21% de adultos, lo que supone más de 75.000 afectados aproximadamente, aunque esta enfermedad también puede debutar en la infancia.

2. publications.aap.org › pediatrics › articleIncorrect Administration of Adult RSV Vaccines to Young Children

   publications.aap.org › pediatrics › article

   • En caché

   Hace 10 horas · In May 2023, the US Food and Drug Administration (FDA) approved the first vaccines for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) for use in adults aged ≥60 years: 1 manufactured by GSK (Arexvy)1 and 1 by Pfizer (Abrysvo).2 In July 2023, FDA approved nirsevimab (Beyfortus, Sanofi, and AstraZeneca), a long-acting monoclonal antibody ...

3. finance.yahoo.com › news › gsk-lon-gsk-paying-dividend-053727741GSK (LON:GSK) Is Paying Out A Dividend Of £0.15 - Yahoo Finance

   finance.yahoo.com › news › gsk-lon-gsk-paying-dividend-053727741

   • En caché

   Hace 10 horas · GSK plc's investors are due to receive a payment of £0.15 per share on 11th of July. The dividend yield will be 3.3% based on this payment which is still above the industry average. See our ...

4. uk.finance.yahoo.com › news › stock-market-2-best-shares-090726713New to the stock market? Here are 2 of the best shares to...

   uk.finance.yahoo.com › news › stock-market-2-best-shares-090726713

   • En caché

   Hace 10 horas · GSK. The first is GSK (LSE: GSK). It’s a pharmaceutical giant that delivers over 1.5m doses of its vaccines every day. The stock’s got off to a hot start in 2024, rising 20%. What I most like about GSK is the defensive nature of the stock. By that, I mean it offers investors, to a certain extent, protection against tough economic conditions.

5. biotech-today.com › gsk-tips-12-blockbuster-launches-to-soften-hiv-patent-lossGSK tips 12 blockbuster launches to soften HIV patent loss, power...

   biotech-today.com › gsk-tips-12-blockbuster-launches-to-soften-hiv-patent-loss

   • En caché

   Hace 10 horas · GSK is moving to ease worries about the looming loss of exclusivity on its HIV blockbuster, setting out plans to launch at least 12 major products and deliver more than 38 billion pounds sterling ($48 billion) in risk-adjusted sales by 2031. The company expects dolutegravir, which brought in (PDF) 5.4 billion pounds last year, to…

6. vidadigital.com.pa › panama-centro-de-discusion-regional-tecnologia-y-medicinaPanamá centro de discusión regional: tecnología y medicina se...

   vidadigital.com.pa › panama-centro-de-discusion-regional-tecnologia-y-medicina

   • En caché

   Hace 10 horas · En un esfuerzo continuo por liderar la innovación en el tratamiento de enfermedades respiratorias, GSK, empresa biofarmacéutica global con presencia en Panamá llevó a cabo la primera edición de «Asthma Connect» en el país.

7. www.pharmajournalist.com › bioversys-announces-expansion-of-strategicBioVersys Announces Expansion of Strategic Collaboration with GSK...

   www.pharmajournalist.com › bioversys-announces-expansion-of-strategic

   • En caché

   Hace 10 horas · BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced the expansion of its strategic collaboration with the global biopharma company GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098 ...